Provenge, an individually tailored immunotherapy vaccine for prostate cancer has been approved in the US for advance case treatment. The vaccine cost about $93,000 per patient and invokes an individual's immune response to cancerous cells. Currently, prostate cancer accounts for about 12% of male cancer deaths. http://news.bbc.co.uk/2/hi/health/8654039.stm